OABI (OmniAb) EBIT: $-60.95 Mil (TTM As of Mar. 2026)

What is OmniAb EBIT?

OmniAb OABI +1.47% 71 EBIT is $-60.95 Mil as of Mar. 2026. GuruFocus rates OABI with a GF Score™ of 71/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 4 warning signs investors should review.

OmniAb's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-7.83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-60.95 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OmniAb's annualized ROC % for the quarter that ended in Mar. 2026 was -12.73%. OmniAb's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -112.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. OmniAb's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -18.96%.

OmniAb (NAS:OABI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OmniAb's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-31.316 * ( 1 - 0% )	/	( (249.619	+	242.322)	/ 2 )
=	-31.316	/	245.9705
=	-12.73 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	300.914	-	2.208	-	( 54.025	-	max(0, 16.254	-	65.341	+	54.025	))
=	249.619

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	293.65	-	2.256	-	( 49.072	-	max(0, 13.566	-	65.125	+	49.072	))
=	242.322

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

OmniAb's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-31.316	/	( ( (24.973 + max(-1.059, 0))	+	(24.07 + max(6.427, 0)) )	/	2 )
=	-31.316	/	( ( 24.973	+	30.497 )	/	2 )
=	-31.316	/	27.735
=	-112.91 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7.39	+	0	+	3.926)	-	(2.208	+	3.161	+	7.006)
=	-1.059

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(12.639	+	0.92	+	2.494)	-	(2.256	+	2.941	+	4.429)
=	6.427

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

OmniAb's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-60.954	/	321.432
	=	-18.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OmniAb EBIT Related Terms

OmniAb EBIT Historical Data

* Premium members only.

The historical data trend for OmniAb's EBIT can be seen below:

OmniAb EBIT Chart

OmniAb Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-34.34

-26.65

-69.42

-74.50

-68.97

OmniAb Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-18.84	-19.22	-18.14	-15.77	-7.83

OABI vs VNDA, AVIR, UPB: EBIT Comparison

For the Biotechnology subindustry, OmniAb's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OmniAb's EV-to-EBIT falls into.

Save Embed

71GF Score

OmniAb Inc OABI

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

OmniAb EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.95 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-60.95 Mil mean?

OmniAb (OABI) has a EBIT of $-60.95 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on OmniAb.

Is OmniAb's EBIT too high?

OmniAb's current EBIT is $-60.95 Mil. Overall, OmniAb has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does OmniAb's EBIT compare to VNDA and AVIR?

OmniAb's EBIT of $-60.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on OmniAb. OmniAb's current EBIT is $-60.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is OmniAb stock overvalued right now?

Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.42 — trading 6.6% above its estimated fair value. The current EBIT is $-60.95 Mil. OmniAb's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For OmniAb (OABI), the current EBIT is $-60.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OmniAb (OABI) Overvalued in 2026?

Based on GuruFocus' analysis, OmniAb stock appears to be overvalued. The current stock price of $2.42 is trading 6.6% above its estimated GF Value™ of $2.27. GuruFocus considers OmniAb to be Fairly Valued.

Key valuation signals for OABI:

EBIT: $-60.95 Mil
GF Value™: $2.27 vs. price of $2.42 (6.6% above fair value)
GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OmniAb Business Description

Industry Healthcare Biotechnology

Comparable Companies VNDA AVIR UPB TENX RCKT DMAC LXEO PROK PRLD CMPX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608

Website https://www.omniab.com

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

71GF Score

Get the complete analysis for OABI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.42

Price

$2.27

GF Value

View OABI Analysis

See EBIT data for all stocks →